Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus
Microbiology Spectrum · 02.07.2024 · 12 (7)
DOI: 10.1128/spectrum.02164-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.07.2024. Verfasst von Zezhong Zheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: South China Agricultural University, Guangzhou, China. Hauptthemen laut MEDLINE: African Swine Fever Virus, CRISPR-Cas Systems, African Swine Fever, Gene Editing. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
African swine fever (ASF) is a highly fatal viral disease that poses a significant threat to domestic pigs and wild boars globally. In our study, we aimed to explore the potential of a multiplexed CRISPR-Cas system in suppressing ASFV replication and infection. By engineering CRISPR-Cas systems to target nine specific loci within the ASFV genome, we observed a substantial reduction in viral replication in vitro . This reduction was achieved through the concerted action of both Type II and Type III RNA polymerase-guided gRNA expression. To further evaluate its anti-viral function in vivo , we developed a pig strain expressing the multiplexable CRISPR-Cas-gRNA via germline genome editing. These transgenic pigs exhibited normal health with continuous expression of the CRISPR-Cas-gRNA system, and a subset displayed latent viral replication and delayed infection. However, the CRISPR-Cas9-engineered pigs did not exhibit a survival advantage upon exposure to ASFV. To our knowledge, this study represents the first instance of a living organism engineered via germline editing to assess resistance to ASFV infection using a CRISPR-Cas system. Our findings contribute valuable insights to guide the future design of enhanced viral immunity strategies. IMPORTANCE ASFV is currently a devastating disease with no effective vaccine or treatment available. Our study introduces a multiplexed CRISPR-Cas system targeting nine specific loci in the ASFV genome. This innovative approach successfully inhibits ASFV replication in vitro , and we have successfully engineered pig strains to express this anti-ASFV CRISPR-Cas system constitutively. Despite not observing survival advantages in these transgenic pigs upon ASFV challenges, we did note a delay in infection in some cases. To the best of our knowledge, this study constitutes the first example of a germline-edited animal with an anti-virus CRISPR-Cas system. These findings contribute to the advancement of future anti-viral strategies and the optimization of viral immunity technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- South China Agricultural University, Guangzhou, China.
- Qihan Biotechnology, Hangzhou, China.
- Yunan Agriculture University, Kunming, China.
- Harvard University, Cambridge, Massachusetts, USA.
ORCID-Profile: Jiapan Hu, Luhan Yang
Zitieren
APA
Zheng, Z., Xu, L., Gao, Y., Dou, H., Zhou, Y., Feng, X., He, X., Tian, Z., Song, L., Mo, G., Hu, J., Zhao, H., Wei, H., Church, G. M., & Yang, L. (2024). Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus. Microbiology Spectrum, 12(7). https://doi.org/10.1128/spectrum.02164-23
Vancouver
Zheng Z, Xu L, Gao Y, Dou H, Zhou Y, Feng X, et al. Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus. Microbiology Spectrum. 2024;12(7). doi:10.1128/spectrum.02164-23
BibTeX
@article{Zheng2024,
author = {Zheng, Zezhong and Xu, Lei and Gao, Yangbin and Dou, Hongwei and Zhou, Yixuan and Feng, Xu and He, Xiangjun and Tian, Zhen and Song, Lingling and Mo, Guolong and Hu, Jiapan and Zhao, Hongye and Wei, Hongjiang and Church, George M and Yang, Luhan},
title = {Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus},
journal = {Microbiology Spectrum},
year = {2024},
volume = {12},
number = {7},
doi = {10.1128/spectrum.02164-23}
}
EUVIMED